- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04358315
Consumer Assessment of Tobacco Flavor and Odor
April 16, 2024 updated by: Roswell Park Cancer Institute
This trial studies consumer assessments of tobacco flavor and odor.
This study will compare the ability of expert and consumer panels to identify and characterize flavors, determine threshold detection levels for individual and mixed flavors, and identify the dominant flavor of mixtures.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. Develop consumer (untrained) sensory panels to identify and assess characterizing flavors in electronic (e)-liquids.
OUTLINE:
Non-user panelists smell and user panelists puff flavored e-liquids and answer questions about the products.
Study Type
Observational
Enrollment (Estimated)
70
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
Buffalo, New York, United States, 14263
- Recruiting
- Roswell Park Cancer Institute
-
Contact:
- Richard J. O'Connor
- Phone Number: 716-845-4517
- Email: Richard.OConnor@roswellpark.org
-
Principal Investigator:
- Richard J. O'Connor
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
Current daily vapers and nonusers in the greater Buffalo and Rochester areas
Description
Inclusion Criteria:
- CONSUMER USER: Current daily vapers of products containing nicotine
- CONSUMER USER: No concurrent use of other tobacco products
- CONSUMER USER: General good health
- CONSUMER USER: No allergies
- CONSUMER USER: No self-reported taste or smell deficits
- CONSUMER USER: Not pregnant or lactating
- CONSUMER USER: No medications known to interfere with taste/smell
- CONSUMER USER: Passing scores on the Brief Smell Identification Test (B-SIT), phenylthiocarbamine (PTC) and 6-n-propylthiouracil (PROP) smell and taste tests
- CONSUMER USER: No positive diagnosis of COVID-19 within 30 days
- CONSUMER NONUSER: No use of tobacco or nicotine products in the last year
- CONSUMER NONUSER: General good health
- CONSUMER NONUSER: No allergies
- CONSUMER NONUSER: No self-reported taste or smell deficits
- CONSUMER NONUSER: Not pregnant or lactating
- CONSUMER NONUSER: No medications known to interfere with taste/smell
- CONSUMER NONUSER: Passing scores on the Brief Smell Identification Test (B-SIT), phenylthiocarbamine (PTC) and 6-n-propylthiouracil (PROP) smell and taste tests
- CONSUMER NONUSER: No positive diagnosis of COVID-19 within 30 days
Exclusion Criteria:
- CONSUMER USER: Outside age range
- CONSUMER USER: Not current daily vapers
- CONSUMER USER: Concurrent use of other tobacco products
- CONSUMER USER: Fair or poor general health
- CONSUMER USER: Allergies
- CONSUMER USER: Self-reported taste or smell deficits
- CONSUMER USER: Pregnant or lactating
- CONSUMER USER: Medications known to interfere with taste/smell
- CONSUMER USER: Failing scores on the Brief Smell Identification Test (B-SIT), phenylthiocarbamine (PTC) and 6-n-propylthiouracil (PROP) smell and taste tests
- CONSUMER USER: Positive diagnosis of COVID-19 within 30 days
- CONSUMER NONUSER: Outside age range
- CONSUMER NONUSER: Use of tobacco or nicotine products in the last year
- CONSUMER NONUSER: Fair or poor general health
- CONSUMER NONUSER: Allergies
- CONSUMER NONUSER: Self-reported taste or smell deficits
- CONSUMER NONUSER: Pregnant or lactating
- CONSUMER NONUSER: Medications known to interfere with taste/smell
- CONSUMER NONUSER: Failing scores on the Brief Smell Identification Test (B-SIT), phenylthiocarbamine (PTC) and 6-n-propylthiouracil (PROP) smell and taste tests
- CONSUMER NONUSER: Positive diagnosis of COVID-19 within 30 days
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Observational (smell or puff e-liquids)
All panel participants smell and user panelists puff flavored e-liquids and answer questions about the products.
|
Ancillary studies
Smell or puff e-liquids
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Flavor identification and evaluation
Time Frame: Up to 12 months
|
Subjects will be asked to identify various concentrations of flavored e-liquids
|
Up to 12 months
|
Specific flavor detection thresholds
Time Frame: Up to 12 months
|
Subjects will rate intensity of odors of e liquids
|
Up to 12 months
|
Flavor combination thresholds
Time Frame: Up to 12 months
|
Subjects will rate a combination of two e-liquids combined
|
Up to 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Richard J O'Connor, Roswell Park Cancer Institute
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 3, 2023
Primary Completion (Estimated)
October 3, 2027
Study Completion (Estimated)
October 3, 2027
Study Registration Dates
First Submitted
April 13, 2020
First Submitted That Met QC Criteria
April 20, 2020
First Posted (Actual)
April 24, 2020
Study Record Updates
Last Update Posted (Actual)
April 17, 2024
Last Update Submitted That Met QC Criteria
April 16, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- I 80518 (Other Identifier: Roswell Park Cancer Institute)
- U54CA228110 (U.S. NIH Grant/Contract)
- NCI-2019-06320 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Subject
-
Changchun GeneScience Pharmaceutical Co., Ltd.Completed
-
CelltrionCompletedHealthy SubjectKorea, Republic of
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)Active, not recruiting
-
Staidson (Beijing) Biopharmaceuticals Co., LtdCompleted
-
GeneScience Pharmaceuticals Co., Ltd.Completed
-
Kyowa Kirin Co., Ltd.Completed
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingHealthy SubjectUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Texas A&M UniversityCompletedHealthy SubjectUnited States
-
Whanin Pharmaceutical CompanyCompletedHealthy SubjectKorea, Republic of
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute...Active, not recruitingHealthy SubjectUnited States
Clinical Trials on Questionnaire Administration
-
Fondazione Don Carlo Gnocchi OnlusUnknown
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
Istanbul Aydın UniversityCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBreast Carcinoma | Fallopian Tube Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Deleterious CDH1 Gene Mutation | Deleterious DICER1 Gene Mutation | Deleterious SMARCA4 Gene Mutation | Deleterious STK11 Gene MutationUnited States
-
Hospital Clínico Universitario de ValladolidRed Centinela Sanitaria de Castilla y León (RCSCYL); Centro Nacional de Gripe... and other collaboratorsRecruitingMigraine | Headache Disorders | Viral Infection | Influenza -Like Illness | Head PainSpain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | COVID-19 Infection | Hereditary Breast CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent LeukemiaUnited States
-
I.M. Sechenov First Moscow State Medical UniversityAgency of Social Information St. PetersburgActive, not recruiting
-
I.M. Sechenov First Moscow State Medical UniversityActive, not recruitingShoulder ArthropathyRussian Federation